



Thota Ganesh, PhD. (Associate Professor)

- Dr. Ganesh has training and expertise in medicinal chemistry, drug discovery and pharmacology.
- Disease Areas of Interest: Traumatic brain injury, epilepsy and Alzheimer's disease
- The overall research goal of Dr. Ganesh laboratory is to bring safe and effective therapeutic agents for a medically unmet neurodegenerative diseases

Highlights

Selected Latest Key Publications

1. Banik, A.; Amaradhi, R.; Lee, D.; Sau, M.; Wang, W.; Dingledine, D.; Ganesh, T. Prostaglandin receptor EP2 antagonist ameliorates neuroinflammation in two-hit mouse model of Alzheimer's disease. *Journal of Neuroinflammation*. **2021** 18 (1) 273. PMID: 34801055; PMCID: PMC8605573

2. Rawat, V.; Banik, A.; Amaradhi, R.; Rojas, A.; Taval, S.; Nagy, T.; Dingledine, R.; **Ganesh, T.** Pharmacological antagonism of EP2 receptor does not modify basal cardiovascular and respiratory function, blood cell counts, and bone morphology in animal models. *BioMed Pharmacother.*, **2022**. 147: 1122646. PMID: 35091236;

Awards and other significant contributions

1. Recipient of Innovator of the year for 2018
2. Co-founder of Pyrefin Inc., (A biotechnology company)
3. 6 Issued patents. This year 2 patents entered to national stage for review.

Ganesh group, 2021-2022

